NCT07707648 Evaluation of the Feasibility and Safety of ENCER for Cancer Treatment-Related Fatigue in Patients Receiving Chemotherapy or Radiotherapy
| NCT ID | NCT07707648 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Beaura for Para Pharmaceutical Products Trading LLC |
| Condition | Fatigue Related to Cancer Treatment |
| Study Type | INTERVENTIONAL |
| Enrollment | 74 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 74 participants in total. It began in 2025-10-01 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a feasibility, double blind, placebo-controlled clinical study designed to evaluate the effect of 'Encer' on Cancer treatment Related Fatigue. 'Encer' is a combination of 5 Homeopathic Medical Product (HMP). The five HMPs are registered in the Homeopathic Pharmacopeia of the United States and the current investigational treatment 'Encer' is authorized for over-the-counter sales in the USA by NDC number. The study aims to test the efficacy of 'Encer' in treating Cancer Treatment-Related Fatigue (CTRF) among cancer patients treated with chemotherapy and or radiotherapy using the Physiological measurements using Garmin vivosmart 5 and the Functional Assessment of Chronic Illness Therapy -Fatigue (FACIT-F). This feasibility study will include patients that will be randomly assigned to either Placebo or Treatment in 1:1 ratio.
Eligibility Criteria
Inclusion Criteria: 1. Subject's informed consent 2. Either male or female 3. Age 18 and above 4. Diagnosed with cancer (any type of solid tumor) 5. Patients planned for their initial treatment or a new regimen of chemotherapy, (at least 4 treatments planned within 12 weeks) a new regimen of radiotherapy (at least 15 fractions planned) 6. Able to interface with digital questionnaire sent to the patient electronically 7. Willing to wear a smartwatch that will detect physiological measurements for the duration of the trial 8. Not currently treated with homeopathic remedy (for at least one week prior to study treatment) Exclusion Criteria: 1. Unable to give informed consent 2. Planned Radiotherapy for less than 15 fractions 3. Chemotherapy anticipated for less than 12 weeks, or fewer than 4 treatments 4. Life expectancy of less than 3 months 5. Patient is a dependent of the sponsor, of the investigational team or his/her immediate family 6. Pregnant or nursing women
Frequently Asked Questions
Who can join the NCT07707648 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Fatigue Related to Cancer Treatment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07707648 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07707648 currently recruiting?
Yes, NCT07707648 is actively recruiting participants. Visit ClinicalTrials.gov or contact Beaura for Para Pharmaceutical Products Trading LLC to inquire about joining.
Where is the NCT07707648 trial being conducted?
This trial is being conducted at Tel Aviv, Israel.
Who is sponsoring the NCT07707648 clinical trial?
NCT07707648 is sponsored by Beaura for Para Pharmaceutical Products Trading LLC. The trial plans to enroll 74 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.